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Objective To assess the prevalence of TT virus (TTV) infection in a series of patients
with chronic hepatitis C virus (HCV) infection, with or without benign (mixed cryoglo-
bulinemia) or malignant (B-cell non-Hodgkin lymphoma (B-NHL)) lymphoproliferative
disease.
Methods Sixty-six HCV patients were studied, including patients with mixed cryo-
globulinemia (n¼ 30), B-NHL (n¼ 15), and no mixed cryoglobulinemia or B-NHL
(n¼ 21). All HCV patients had increased transaminase levels and were HCV RNA
positive. Patients were considered to have mixed cryoglobulinemia if two successive
determinations of their serum cryoglobulin level were above 0.05 g/L. Mixed cryoglo-
bulinemia-negative patients never had mixed cryoglobulins in their serum on multiple
determinations. Subjects without HCV infection included 79 patients with histologically
proven B-NHL, and 50 healthy blood donors. Serum samples were analyzed for TTV
DNA by nested polymerase chain reaction, with two couples of primers in different
regions of the genome, in two independent laboratories.
Results In the group of HCV-positive patients, TTV DNA was found in one of 15 (6.7%)
patients with B-NHL, and in nine of 51 (17.6%, P¼ 0.43) of those without B-NHL. Among
HCV-positive patients without B-NHL, TTV DNA was more frequently found in those
with type II mixed cryoglobulinemia vasculitis than in those without it (six of 16 (37.5%)
versus two of 21 (9.5%), P¼ 0.05). In subjects without HCV infection,TTV DNA was present
in 10 of 79 (12.7%) patients with B-NHL and in seven of 50 (14.0%, P¼ 0.82) blood donors.
Conclusion In patients chronically infected with HCV, TTV co-infection: (1) is not
associated with the presence of B-NHL; and (2) is more frequently found in patients
presenting a type II mixed cryoglobulinemia vasculitis.
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The most frequent extrahepatic manifestation
associated with hepatitis C virus (HCV) infection
is type II mixed cryoglobulinemia, which is a low-
grade lymphoproliferative disease, found in 40–
80% of cases [1–6]. Recent studies have suggested
that other malignant lymphoproliferative diseases
may be associated with chronic HCV infection [7–
10]. A particularly high rate of HCV infection has
been found in patients with B-cell non-Hodgkin
lymphoma (B-NHL) [11,12]. Factors associated
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with mixed cryoglobulinemia or B-NHL in patients
with HCV chronic infection remain unknown.
TT virus (TTV) is a single-stranded DNA virus
recently cloned from a patient with post-transfu-
sion hepatitis [13]. This virus belongs to a new
virus family designated Circinoviridae [14]. The
analysis of its genetic organization reveals that the
virus has a genome of approximately 3800 nucleo-
tides. The TTV genome includes at least two
hypothetical open reading frames (ORF1 and
ORF2), composed, respectively, of 770 and 202
nucleotides, and several genotypes of TTV have
been reported [13–15]. TTV DNA has been found
to be associated with various liver diseases,
including cryptogenetic cirrhosis, fulminant hepa-
titis [16–19] and hepatocellular carcinoma [20,21],
but it is still unknown whether TTV can cause liver
or non-liver disease in humans [22,23]. A high
prevalence of TTV infection has been reported
in bone marrow transplant recipients, with possi-
ble replication in hematopoietic cells [24].
To investigate a possible role of TTV in extra-
hepatic immunologic disorders associated with
HCV chronic infection, we performed a study to
assess the prevalence of TTV DNA in a series of
patients with chronic HCV infection with or with-
out benign (mixed cryoglobulinemia) or malignant
(B-NHL) lymphoproliferative disease.
P A T I E N T S
We studied different groups of consecutive
patients with or without chronic HCV infection,
and with or without B-NHL, from the Internal
Medicine Department or Hematology Department
of our university hospital.
Fifty-one patients (21 males, 30 females, mean
age 55 years (range 18–81)) had chronic HCV infec-
tion without NHL. Chronic HCV infection was
defined by alanine aminotransferase levels of
more than twice the upper limit of the normal
range, anti-HCV antibodies detected by third-
generation tests (ELISA), liver biopsy findings
compatible with chronic hepatitis C, and no other
cause of liver dysfunction (e.g. chronic hepatitis B,
autoimmune hepatitis or primary biliary cirrho-
sis). HCV–mixed cryoglobulinemia-associated
vasculitis was noted in 16 out of 51 patients
who had type II mixed cryoglobulinemia and at
least one of the following clinical features: periph-
eral neuropathy, glomerulonephritis, skin pur-
pura, or cerebral vasculitis. Fourteen HCV
patients had type III cryoglobulins without any
associated extrahepatic manifestation, particularly
without vasculitis. Twenty-one HCV-positive
patients never had cryoglobulinemia on multiple
determinations.
Ninety-four patients (30 males, 64 females,
mean age 58 years (range 23–78)) had B-NHL, with
(n¼ 15) or without (n¼ 79) chronic HCV infection.
Lymphoma was diagnosed on the basis of mor-
phologic evaluation of lymph node or extranodal
tissue, including bone marrow. B-NHL was histo-
logically classified using the Revised European-
American Lymphoma (REAL) classification [25].
In addition, we studied a control group includ-
ing 50 healthy blood donors (19 males, 31 females,
mean age 51 years (range 22–67)) with normal
levels of serum alanine aminotransferase, and
without anti-HCV antibodies, cryoglobulinemia
or lymphoma.
No subjects in either group were HIV positive.
M E T H O D S
HCV serum markers
The serologic status of patients was determined
using two specific third-generation immunoas-
says, a microparticle enzyme immunoassay
(Axsym HCV version 3.0, Abbott, Les Ulis, France)
and an indirect immunoenzymatic technique
(Monolisa anti-HCV Plus, Sanofi Diagnostic Pas-
teur, Marne la Coquette, France) performed
according to the manufacturers’ instructions. A
patient was defined as positive when the two tests
were positive according to each test specification.
Sera used to detect HCV RNA were stored at
80 8C and not thawed prior to use, to avoid false
negativity due to RNA destruction by RNases and
false positivity due to contamination [26]. Serum
RNA was extracted, reverse transcribed to make
cDNA, and amplified by PCR as previously
described [27]. HCV genotyping was performed
using a second-generation Line Probe Assay
(LiPA, Innogenetics, Brussels, Belgium), which
identifies the HCV main types and subtypes. All
sera were negative for anti-HIV antibodies using
commercial immunoassays (Abbott Laboratories,
Diagnostic Pasteur, Paris, France).
Detection and characterization of cryoglobulins
Cryoglobulins were isolated from the patients’ sera,
purified, and characterized by immunoblotting at
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37 8C as previously described [28]. In the present
study, patients were considered to have a signifi-
cant cryoglobulinemia if they had a minimum
serum cryoglobulin level of 0.05 g/L in two deter-
minations. Following the system of Brouet et al.
[29], patients had either type II or type III mixed
cryoglobulins, characterized, respectively, by the
presence of a monoclonal or polyclonal rheuma-
toid factor component.
TTV DNA determination
All serum samples were analyzed for TTV DNA by
nested polymerase chain reaction (PCR) in two
independent laboratories in Marseille, France
(Laboratory of Biochemistry, Hoˆpital La Concep-
tion, and Alphabio Laboratory). These two labora-
tories were selected for their ability to detect TTV
from the 17 French laboratories specialized in
molecular biology which belong to the GEMHEP
group (the French Group of Molecular Study of
Viral Hepatitis) [30]. TTV DNA detection was
performed by PCR using two methods. The first
method was based on an in-house PCR with the
fully nested primers described by Simmonds et al.
[15]. The second method, chosen by the GEMHEP
group, was based on a hemi-nested PCR with
degenerated primers derived from those described
by Okamoto et al. [in 30]. A panel of controls
prepared by an external investigator included 12
frozen samples: seven positive controls (obtained
from five blood donors and two patients under
hemodialysis), and five negative controls.
Liver biopsy
Histologic examination of liver biopsies included
qualitative and quantitative analyses of the inflam-
matory activity and severity of fibrosis, which
were classified using Knodell’s score.
Statistical analysis
Statistical analysis used chi-square or Fisher’s
exact test for comparisons of percentages. Mean
quantitative values were compared using the
unpaired Student’s t-test. Non-parametric analyses
were done with the Mann–Whitney U-test. A
Wilcoxon rank sum test was computed for ordinal
variables. An assessment of the characteristics of
HCV infection (age, gender, genotype, liver fibro-
sis) associated with TTV DNA positivity was per-
formed using univariate and multivariate (logistic
regression) analyses. All calculated P-values are
two-tailed. Significance was assessed at P¼ 0.05.
R E S U L T S
In the group of HCV-positive patients, TTV DNA
was found in one of 15 (6.7%) patients with B-NHL
and nine of 51 (17.6%) of those without B-NHL
[Table 1]. Among HCV-positive patients without
B-NHL, TTV DNA was more frequently found in
those with, compared to those without, type II
mixed cryoglobulinemia vasculitis (six of 16
(37.5%) versus two of 21 (9.5%), P¼ 0.05). This
difference was not associated with greater expo-
sure to blood tranfusion or intravenous drug
abuse. The modes of acquiring HCV infection in
patients with or without type II mixed cryoglobu-
linemia vasculitis were not different, i.e. transfu-
sion (10/16 versus 12/21), intravenous drug abuse
(3/16 versus 6/21), and unknown (3/16 versus 3/
21). No factor tested showed a significant differ-
ence between TTV DNA-positive or -negative
patients, i.e. age, gender, HCV genotype, liver
Table 1 Prevalence of serum TTV DNA in a series of patients with chronic HCV infection, with or without benign (mixed
cryoglobulinemia) or malignant (B-NHL) lymphoproliferative disease
TTV positive
(number) Number of patients
TTV positive
(%)
HCV type II mixed cryoglobulinemia 6 16 37.5
HCV type III cryoglobulin 1 14 7.1
HCV positive, cryoglobulin-negative,
without B-NHL
2 21 9.5
HCV positive with B-NHL 1 15 6.7
HCV negative with B-NHL 10 79 12.7
Healthy blood donorsa 7 50 14.0
HCV, hepatitis C virus; B-NHL, B-cell non Hodgkin lymphoma.
aHCV-negative without B-NHL.
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fibrosis. In subjects without HCV infection, TTV
DNA was present in 10 of 79 (12.7%) patients with
B-NHL and seven of 50 (14.0%, P¼ 0.82) blood
donors. TTV DNA was found with a 100% con-
cordance with both PCR methods in both inde-
pendent laboratories.
D I S C U S S I O N
Benign (mixed cryoglobulinemia) or malignant (B-
NHL) lymphoproliferative disease has been fre-
quently reported in association with chronic HCV
infection [4–12]; the factors associated with such
lymphoproliferative diseases in patients with
HCV chronic infection remain unknown. TTV is
a single-stranded DNA virus recently cloned from
a patient with post-transfusion hepatitis [13]. TTV
has been thought to be a new hepatitis virus, but to
date it is still unknown whether TTV are respon-
sible for liver disease or other diseases in humans
[22,23].
The prevalence of TTV DNA in European and
North American patients with chronic HCV infec-
tion has been reported to range from 12.5% [31,32]
to 27% [33]. In the present study, we found a 17.6%
prevalence of TTV DNA in French HCV-positive
patients, which in agreement with these studies.
We did not find a correlation between age, sex,
HCV genotype, liver fibrosis, and TTV DNA posi-
tivity [34,35]. The prevalence of TTV DNA in
patients with B-NHL was low and not different
from that in blood donors, whether they had
(6.7%) or did not have (12.7%) chronic HCV infec-
tion. The mechanism(s) that may promote B-NHL
in HCV patients remains to be determined.
More interestingly, we found a higher preva-
lence of TTV DNA in HCV patients with type II
mixed cryoglobulinemia vasculitis compared to
those without cryoglobulinemia. This difference
could not be attributed to a higher exposure to
blood tranfusion, intravenous drug abuse, or other
confounding factors such as frequent hospital
admissions, parenteral exposures, or plasmapher-
esis, none of which were statistically different in
these populations. Previous studies searching for
factors that may promote mixed cryoglobulin pro-
duction, whether viral (HCV genotype, HCV vir-
emia) [36–39], immunologic (immunoglobulin or
lymphocyte subsets) [27,40], or infectious (hepati-
tis G virus, parvovirus B19) [41,42], were negative.
One possible mechanism for the development of
vasculitis in HCV patients with mixed cryoglobu-
linemia suggested by Agnello and Abel [43] is that
a small, high-molecular-weight small portion of
the cryoglobulins initiate activation of endothelial
cells, leading to altered vascular permeability,
neutrophil infiltration, and vessel damage. An
alternative mechanism involves hepatitis C
virus-induced endothelial damage, as suggested
by the finding of HCV antigen in normal vascular
endothelial cells [44], anti-endothelial cell anti-
body-induced apoptosis [45], and excessive pro-
duction of anti-endothelial cell antibodies in HCV
cryoglobulinemia vasculitis [46]. TTV co-infection
may then increase endothelial cell alterations,
leading to more frequent mixed cryoglobulinemia
vasculitis in HCV patients. The results, when test-
ing for TTV DNA, are highly dependent on the
primers chosen to detect the virus [47,48]. It is
possible that the primers used in the present study
underestimated the prevalence of TTV infection.
C O N C L U S I O N
In patients chronically infected with HCV, TTV
coinfection [1] is not associated with the presence
of B-NHL [2], and is more frequently found in
patients with type II mixed cryoglobulinemia vas-
culitis.
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